GO:0042158 lipoprotein biosynthetic process: Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0042158 (lipoprotein biosynthetic process) describes the chemical reactions and pathways that form conjugated, water-soluble proteins whose covalently attached nonprotein group is one or more lipids.
• Lipoproteins are assembled from apolipoproteins plus lipid cargo, and their biosynthesis is central to moving triglycerides, cholesterol, and phospholipids through plasma.
• Triglyceride-rich lipoproteins such as VLDL and chylomicrons are products of this process, and their production is regulated by ANGPTL3, ANGPTL4, and ANGPTL8.
• The pathway is physiologically essential: defects in lipoprotein formation and clearance underlie dyslipidemias, atherosclerosis, and cardiometabolic disease.
• Lipoprotein biosynthesis can be studied with CRISPR knockout, point-mutation, knock-in, and overexpression models combined with lipidomics, proteomics, and imaging.
• Bacterial lipoprotein biosynthesis, exemplified by LolCDE, shows that lipoprotein assembly and transport are conserved, mechanistically tractable processes.
Description
GO:0042158, lipoprotein biosynthetic process, is the biological process by which cells produce conjugated, water-soluble proteins in which the covalently attached nonprotein group consists of a lipid or lipids. In practice, this means the assembly of apolipoproteins with cholesterol, triglycerides, phospholipids, and other lipids into particles that can be secreted and transported in the aqueous environment of plasma. The term is therefore central to understanding how dietary and hepatic lipids are packaged, delivered, and cleared. Lipoprotein biosynthesis matters because it sits at the intersection of lipid metabolism, cardiovascular biology, and metabolic disease. Triglyceride-rich lipoproteins are directly linked to atherosclerotic risk, and the ANGPTL family controls their production and lipolysis. Endocytic uptake of lipoproteins further connects biosynthesis to clearance pathways and to disorders such as familial hypercholesterolemia. For researchers, GO:0042158 provides a precise ontology anchor for experiments that perturb apolipoprotein expression, lipid loading, or secretory trafficking. Because the process is defined by covalent lipid attachment and particle formation, it can be interrogated with genetic, biochemical, and imaging approaches.
lipoprotein biosynthetic process At A Glance
| GO ID | GO:0042158 |
|---|---|
| GO term | lipoprotein biosynthetic process |
| Ontology | biological_process |
| Synonym | lipoprotein anabolism; lipoprotein biosynthesis; lipoprotein formation; lipoprotein synthesis |
| Major function | Formation of conjugated, water-soluble proteins carrying covalently attached lipids, including apolipoprotein-lipid particle assembly |
| Key substrates | Apolipoproteins, triglycerides, cholesterol, phospholipids |
| Key regulators | ANGPTL3, ANGPTL4, ANGPTL8 |
| Related process | Lipoprotein metabolism and endocytosis |
| Representative particles | Chylomicrons, VLDL, LDL, HDL |
What Is GO:0042158?
In our own words, GO:0042158 describes the chemical reactions and pathways that result in the formation of any conjugated, water-soluble protein in which the covalently attached nonprotein group consists of a lipid or lipids. This includes the synthesis and lipid modification of apolipoproteins, their assembly with lipid cargo, and the generation of secreted lipoprotein particles such as chylomicrons, VLDL, and HDL.
Why Is lipoprotein biosynthetic process Important in Cell Biology?
Lipoprotein biosynthetic process is important because it determines how lipids are packaged for transport, how tissues receive energy and membrane precursors, and how excess lipid accumulation is handled. Dysregulation of this process contributes to hypertriglyceridemia, atherosclerosis, and other cardiometabolic conditions, making it a major target for both mechanistic research and therapeutic development.
• Provides the assembly route for triglyceride-rich lipoproteins such as VLDL and chylomicrons.
• Controls plasma lipid transport and delivery of cholesterol and fatty acids to peripheral tissues.
• Is regulated by ANGPTL3, ANGPTL4, and ANGPTL8, which modulate lipoprotein production and lipolysis.
• Connects to endocytic clearance pathways that determine circulating lipoprotein levels.
• Underlies dyslipidemias and atherosclerotic cardiovascular disease risk.
• Is relevant to kidney disease and nephrotic syndrome, where lipoprotein metabolism is altered.
• Provides a conserved model for studying lipid-modified protein transport, as shown by bacterial LolCDE.
• Offers tractable targets for CRISPR-based functional genomics of lipid metabolism.
What Happens During lipoprotein biosynthetic process?
Apolipoprotein synthesis and lipid loading
In simple terms: The cell first makes the protein backbone of a lipoprotein and then attaches lipids to it.
Lipoprotein biosynthesis begins with the synthesis of apolipoproteins, the protein components that confer water solubility and receptor recognition. These proteins are subsequently loaded with lipids, including triglycerides, cholesterol, and phospholipids, to form the conjugated, water-soluble particles defined by GO:0042158. The lipid cargo determines particle size, density, and metabolic fate.
Assembly of triglyceride-rich particles
In simple terms: Lipids and proteins are packaged together into particles that can travel in blood.
A major output of the process is the assembly of triglyceride-rich lipoproteins such as VLDL in the liver and chylomicrons in the intestine. These particles are stabilized by apolipoproteins and carry dietary and hepatic lipids to peripheral tissues. The ANGPTL3-4-8 axis regulates the production and processing of these triglyceride-rich lipoproteins.
Secretion and remodeling
In simple terms: Once assembled, the particle is secreted and can be remodeled in the circulation.
After assembly, lipoprotein particles are secreted into the plasma, where they undergo remodeling through lipolysis and lipid exchange. This remodeling changes particle composition and generates remnants and other lipoprotein classes. Endocytic pathways then mediate the uptake of these particles by cells.
Covalent lipid attachment and water solubility
In simple terms: The defining feature is that lipids are covalently attached to a protein, making it soluble in water-based environments.
The QuickGO definition of GO:0042158 emphasizes conjugated, water-soluble proteins with covalently attached lipids. This covalent lipid modification distinguishes lipoprotein biosynthesis from simple lipid binding and enables the protein-lipid complex to circulate in plasma. Bacterial lipoprotein biosynthesis, as studied in LolCDE, illustrates the conserved principle of lipid-modified protein transport.
Key Genes Involved in GO:0042158 lipoprotein biosynthetic process
The following genes and proteins are central to lipoprotein biosynthetic process and are commonly studied in this pathway.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ANGPTL3 | Regulates triglyceride-rich lipoprotein production and lipolysis | Target for lipid-lowering strategies and functional studies |
| ANGPTL4 | Modulates lipoprotein lipase activity and lipid handling | Links lipoprotein biosynthesis to energy metabolism |
| ANGPTL8 | Regulates ANGPTL3 and ANGPTL4 activity | Controls triglyceride-rich lipoprotein levels |
| APOB | Core apolipoprotein of VLDL, LDL, and chylomicrons | Central to triglyceride-rich lipoprotein assembly |
| APOA1 | Major apolipoprotein of HDL | Relevant to reverse cholesterol transport studies |
| APOE | Mediates lipoprotein recognition and clearance | Linked to lipid transport and neurodegeneration research |
| MTTP | Lipid transfer for apolipoprotein B lipidation | Required for VLDL and chylomicron assembly |
| LPL | Hydrolyzes triglycerides in lipoproteins | Key regulator of lipoprotein remodeling |
| LDLR | Mediates endocytic uptake of LDL | Model for lipoprotein clearance studies |
| LOLCDE | Bacterial lipoprotein transport system | Provides a tractable model for lipid-modified protein transport |
| ABCA1 | Lipid efflux to apolipoproteins | Relevant to HDL biosynthesis |
| CETP | Transfers lipids between lipoproteins | Modulates lipoprotein composition |
| PCSK9 | Regulates LDL receptor levels | Target for cholesterol-lowering research |
| SCARB1 | Mediates selective cholesterol uptake | Relevant to HDL metabolism |
| NR1H2 | Nuclear receptor regulating lipid metabolism | Links transcription to lipoprotein biosynthesis |
| SREBF2 | Controls cholesterol synthesis and uptake | Upstream regulator of lipoprotein pathways |
How Is lipoprotein biosynthetic process Regulated?
Lipoprotein biosynthetic process is regulated at multiple levels, including transcriptional control of apolipoprotein genes and post-translational modulation by the ANGPTL3-4-8 axis. ANGPTL3, ANGPTL4, and ANGPTL8 act as key regulators of triglyceride-rich lipoprotein production and lipolysis, thereby controlling the flux through this pathway. Hormonal and nutritional signals also influence lipoprotein assembly and secretion, as reviewed in lipoprotein physiology.
lipoprotein biosynthetic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ANGPTL3 | Hypertriglyceridemia and cardiovascular risk | Knockout and overexpression models in hepatocytes |
| APOB | Familial hypobetalipoproteinemia and dyslipidemia | Point-mutation knock-in in liver cell lines |
| LDLR | Familial hypercholesterolemia | Knockout and rescue models in hepatocytes |
| APOE | Lipid transport and neurodegeneration | Knock-in of disease-associated variants |
| MTTP | Abetalipoproteinemia | Knockout in intestinal or hepatic cells |
Atherosclerotic cardiovascular disease
Dysregulation of lipoprotein biosynthesis and metabolism leads to elevated triglyceride-rich lipoproteins and contributes to atherosclerosis. ANGPTL3, ANGPTL4, and ANGPTL8 are directly implicated in modulating these risk-associated particles. Endocytic clearance defects further exacerbate lipoprotein accumulation and plaque formation.
Dyslipidemias and metabolic disorders
Disorders of lipoprotein metabolism, including hypertriglyceridemia, arise from altered biosynthesis, secretion, or clearance of lipoproteins. Kidney disease can also perturb lipoprotein metabolism, as reviewed in the context of nephrotic syndrome and renal failure. These conditions highlight the clinical importance of the pathway.
Neurodegeneration and lipid transport
Apolipoproteins such as APOE participate in lipoprotein recognition and transport, linking lipoprotein biology to brain lipid metabolism. Endocytic uptake mechanisms for lipoproteins are relevant to neuronal lipid handling and disease. This connection makes lipoprotein biosynthesis a topic of interest in neurodegeneration research.
From lipoprotein biosynthetic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of ANGPTL3 alter lipoprotein secretion? | CRISPR knockout in hepatocyte cell lines |
| Does a point mutation in APOB affect particle assembly? | Point-mutation knock-in in liver cells |
| Can a tagged apolipoprotein track secretion? | Tagged knock-in of APOB or APOA1 |
| Does overexpression of ANGPTL4 change lipid handling? | Overexpression in cultured cells |
| Is LolCDE required for bacterial lipoprotein transport? | Knockout in bacterial models |
| Does LDLR rescue restore lipoprotein uptake? | Knock-in or overexpression rescue in LDLR-null cells |
How to Study the lipoprotein biosynthetic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Lipidomics | Lipid species and abundance | Quantifying lipoprotein lipid cargo |
| Proteomics | Apolipoprotein composition | Identifying particle protein components |
| Fluorescence imaging | Particle assembly and secretion | Tracking lipoprotein trafficking |
| CRISPR knockout | Loss-of-function effects | Testing gene requirement in lipoprotein biosynthesis |
| CRISPR knock-in | Variant or tag effects | Modeling disease-associated mutations |
| Endocytosis assay | Lipoprotein uptake | Measuring clearance capacity |
| Western blot | Apolipoprotein expression | Validating genetic perturbations |
Lipidomics and proteomics
Mass spectrometry-based lipidomics and proteomics can quantify the lipid and protein composition of lipoprotein particles produced by cells. These methods are essential for verifying that a genetic perturbation alters lipoprotein biosynthesis.
Imaging of lipoprotein secretion
Fluorescence imaging and tagged apolipoproteins allow visualization of particle assembly and secretion in live cells. This approach helps localize the steps of lipoprotein biosynthesis within secretory pathways.
Genetic perturbation with CRISPR
CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal testing of candidate genes in lipoprotein biosynthesis. Such models can be combined with biochemical assays to measure lipid output.
Endocytosis and clearance assays
Endocytosis assays measure the uptake of lipoproteins and complement biosynthesis studies by defining the fate of secreted particles. Receptor-mediated uptake is a key readout of lipoprotein function.
How CRISPR Can Be Used to Study GO:0042158 lipoprotein biosynthetic process
Knockout
CRISPR knockout of genes such as ANGPTL3 or MTTP can reveal their requirement for lipoprotein biosynthesis and secretion. Knockout models are widely used to test loss-of-function effects on lipid particle production.
Point Mutation
Point-mutation knock-in allows precise modeling of disease-associated variants in apolipoproteins or receptors. These models help distinguish pathogenic mutations from benign polymorphisms in lipoprotein pathways.
Knock-in
Tagged knock-in of apolipoproteins enables tracking of lipoprotein assembly and secretion in live cells. Knock-in of reporter or affinity tags supports biochemical purification of lipoprotein particles.
Overexpression
Overexpression of ANGPTL family members or apolipoproteins can drive increased lipoprotein production and reveal regulatory mechanisms. Overexpression models are useful for gain-of-function studies in lipid metabolism.
How EDITGENE Supports lipoprotein biosynthetic process Research
Researchers studying lipoprotein biosynthetic process-related genes often need to determine whether a candidate gene is causally involved in particle assembly, secretion, or clearance. EDITGENE provides the CRISPR and bioinformatics tools to build such causal evidence in relevant cell models.
Contact EDITGENE today to design your custom CRISPR model for lipoprotein biosynthetic process research.
Frequently Asked Questions About lipoprotein biosynthetic process
What is lipoprotein biosynthetic process?
It is the biological process (GO:0042158) that forms conjugated, water-soluble proteins with covalently attached lipids, including apolipoprotein-lipid particle assembly.
What genes are involved in lipoprotein biosynthetic process?
Key genes include ANGPTL3, ANGPTL4, ANGPTL8, APOB, APOA1, APOE, MTTP, and LPL.
What is the GO ID for lipoprotein biosynthetic process?
The GO ID is GO:0042158.
Why is lipoprotein biosynthesis important?
It controls lipid transport and is linked to dyslipidemia, atherosclerosis, and metabolic disease.
How is lipoprotein biosynthesis regulated?
It is regulated by the ANGPTL3-4-8 axis and by transcriptional control of apolipoprotein genes.
What diseases are associated with defects in lipoprotein biosynthesis?
Dyslipidemias, atherosclerotic cardiovascular disease, and abetalipoproteinemia are associated with defects in this pathway.
How can CRISPR be used to study lipoprotein biosynthesis?
CRISPR knockout, point-mutation, knock-in, and overexpression models allow causal testing of genes in this pathway.
What methods measure lipoprotein biosynthesis?
Lipidomics, proteomics, imaging, and endocytosis assays are commonly used.
What are triglyceride-rich lipoproteins?
They are particles such as VLDL and chylomicrons that carry triglycerides and are products of lipoprotein biosynthesis.
What is the role of ANGPTL3 in lipoprotein biosynthesis?
ANGPTL3 regulates triglyceride-rich lipoprotein production and lipolysis.
Conclusion
GO:0042158 lipoprotein biosynthetic process defines the formation of lipid-modified, water-soluble proteins that are essential for lipid transport and metabolic homeostasis. Its regulation by ANGPTL proteins and its links to cardiovascular and metabolic disease make it a high-value research area. CRISPR-based models and multi-omics methods provide powerful tools to dissect this pathway and identify new therapeutic targets.
References
- 1. Sylvers-Davie KL et al.. 2021. Regulation of lipoprotein metabolism by ANGPTL3, ANGPTL4, and ANGPTL8.. Am J Physiol Endocrinol Metab 321(4):E493-E508 PMID: 34338039
- 2. Kockx M et al.. 2018. Triglyceride-Rich Lipoproteins.. Cardiol Clin 36(2):265-275 PMID: 29609756
- 3. Zanoni P et al.. 2018. Endocytosis of lipoproteins.. Atherosclerosis 275:273-295 PMID: 29980055
- 4. Illingworth DR. 1993. Lipoprotein metabolism.. Am J Kidney Dis 22(1):90-7 PMID: 8322800
- 6. Qiao W et al.. 2024. Deciphering the molecular basis of lipoprotein recognition and transport by LolCDE.. Signal Transduct Target Ther 9(1):354 PMID: 39725716
- 8. Ginsberg HN. 1998. Lipoprotein physiology.. Endocrinol Metab Clin North Am 27(3):503-19 PMID: 9785050
